Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Krystal Biotech (NASDAQ:KRYS), a $4.3 billion biotechnology company with impressive gross profit margins of 93.2%, reported insider selling activity. President and CEO Krishnan Krish S, along with his spouse, sold shares of common stock between July 14 and July 16, 2025, for a total value of $5.39 million. The sales, executed under 10b5-1 trading plans, saw prices ranging from $150.00 to $151.79 per share. According to InvestingPro analysis, the company maintains a "GREAT" financial health score of 3.74 out of 5.
Krishnan sold 17,623 shares of Krystal Biotech common stock directly. These sales occurred in multiple transactions. On July 14, 13,400 shares were sold at a weighted average price of $150.2996, with individual trades ranging from $150.00 to $150.98. On July 15, 2,184 shares were sold at a weighted average price of $150.6817, with trades ranging from $150.21 to $151.00, and 900 shares were sold at $151.79. On July 16, 1,389 shares were sold at $150. Following these transactions, Krishnan directly owns 1,508,056 shares of Krystal Biotech. The current share price suggests potential upside, with analyst targets ranging from $176 to $252.
Additionally, Suma M. Krishnan, Krishnan’s spouse, sold 17,900 shares of common stock. On July 14, 13,335 shares were sold at a weighted average price of $150.2906, with trades ranging from $150.00 to $150.97, and 100 shares were sold at $151.79. On July 15, 2,236 shares were sold at a weighted average price of $150.6839, with trades ranging from $150.21 to $151.18, and 800 shares were sold at $151.79. On July 16, 1,529 shares were sold at $150. Following these transactions, Suma M. Krishnan directly owns 1,438,711 shares of Krystal Biotech. InvestingPro data shows the company’s strong fundamentals, with a current ratio of 9.65x and minimal debt.
The sales by Krishnan and his spouse were made under pre-arranged 10b5-1 trading plans adopted on September 12, 2024, which have now terminated, having reached the maximum number of shares to be sold.
Krishnan also indirectly owns 90,000 shares through the Krishnan Spousal Trust and 50,000 shares through the Krishnan Family Trust. Krishnan and his spouse have joint beneficial ownership, voting, and investment control over the Krishnan Family Trust.
In other recent news, Krystal Biotech announced the dosing of the first patient in its Phase 1/2 EMERALD-1 trial, investigating KB801 as a treatment for neurotrophic keratitis (NK), a rare degenerative corneal disease. This trial aims to evaluate the safety and tolerability of KB801, a re-dosable eye drop gene therapy designed to stimulate local nerve growth factor production for corneal healing. Citi has raised its price target for Krystal Biotech to $176, citing the trial’s progress and KB801’s potential advantages over existing treatments. Meanwhile, H.C. Wainwright maintained its Buy rating with a $240 price target, anticipating Krystal Biotech’s upcoming second-quarter 2025 financial results. Clear Street also initiated coverage with a Buy rating and a $190 price target, expressing confidence in the company’s product pipeline, including Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa. The research firm believes Vyjuvek’s continued launch execution could drive further growth. These developments reflect ongoing interest and analysis from various investment firms regarding Krystal Biotech’s current and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.